Ajax's lead program, AJ1-11095, is a first-in-class Type II JAK2 inhibitor currently in Phase 1 clinical development, with first proof-of-concept clinical data to be presented later in 2026
The results signal shift beyond paclitaxel-coated balloon (PCB) angioplasty in femoropopliteal artery disease
_256_384.png)
The company plans a phased expansion across India, focusing initially on metro cities and early-adoption hubs
New acetabular system enhances precision, stability and robotic compatibility in total hip arthroplasty
Deploys $40 million in Hyderabad; advances APIs, peptides, and global small molecule capabilities
The submission is backed by positive results from the Phase 3 AFFIRM study
The lens received U.S. Food and Drug Administration (FDA) market authorization via the De Novo pathway in late 2025
The approval was driven by data from the Phase III TULIP-SC trial
New minimally invasive biomarker test enables earlier diagnosis and improved clinical decision-making, aligned with global guidelines
The centre will leverage AI-enabled tools to support research and diagnostics for complex eye–brain disorders
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
